April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Intervention with Cilostazol Attenuates Retinal Inflammation in a Streptozotocin- Induced Diabetic Animal Model
Author Affiliations & Notes
  • Chang-Hao Yang
    Ophthalmology, National Taiwan Univ Hospital, Taipei, Taiwan
  • Yu-Hsun Huang
    Ophthalmology, National Taiwan Univ Hospital, Taipei, Taiwan
  • Lu-chun Wang
    Ophthalmology, National Taiwan Univ Hospital, Taipei, Taiwan
  • Chung-May Yang
    Ophthalmology, National Taiwan Univ Hospital, Taipei, Taiwan
  • Muh-Shy Chen
    Ophthalmology, National Taiwan Univ Hospital, Taipei, Taiwan
  • Footnotes
    Commercial Relationships  Chang-Hao Yang, None; Yu-Hsun Huang, None; Lu-chun Wang, None; Chung-May Yang, None; Muh-Shy Chen, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 5963. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Chang-Hao Yang, Yu-Hsun Huang, Lu-chun Wang, Chung-May Yang, Muh-Shy Chen; Intervention with Cilostazol Attenuates Retinal Inflammation in a Streptozotocin- Induced Diabetic Animal Model. Invest. Ophthalmol. Vis. Sci. 2011;52(14):5963.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Diabetic retinopathy (DR) remains the leading cause of blindness in developing countries. New evidence indicates that inflammation and oxidative stress may play a central role in the development of DR. The use of appropriate antioxidants may have potential to inhibit the development of DR. Cilostazol, is a phosphodiesterase 3 (PDE3) inhibitor which shows potent anti-inflammatory and anti-oxidative effects. In the present study, we evaluated the effect of cilostazol in a streptozotocin (STZ) induced diabetic rat model.

Methods: : Thirty 6 weeks old female Wistar rats were divided into a normal control group (n=10), a STZ-induce diabetic group (n=10) feed with PBS, and a STZ-induce diabetic group (n=10) feed with cilostazol 18 mg/kg/day. Eight weeks later, the eyeball of each rat was enucleated. We performed PCR, western blot analysis, H&E, and immuno histochemical (IHC) staining to assess the expression of ICAM-1, MCP-1 and Fractalkine (FKN) in the retina. The concentrations of ICAM-1, MCP-1 and FKN in the aqueous humor and vitreous cavity were examined by ELISA. The nuclear factor (NF)-ΚB activity was assessed by IHC and electrophoresis mobility shift assay (EMSA). Besides, the oxidative markers of 8-OHdG, nitrotyrosine and acrolein in the retina were measured by IHC.

Results: : Cilostazol inhibits the increase of ICAM-1, MCP-1 and FKN mRNA and protein expression in the diabetic retina, as well as the increase of ICAM-1, MCP-1 and FKN contents in the aqueous humor and vitreous cavity. Cilostazol attenuated the enhanced activation of NF-ΚB in diabetic rats by IHC and EMSA findings. The levels of oxidatively modified DNA (8-OHdG), nitrotyrosine and oxidative lipids (acrolein) were also diminished in the cilostazol-treated diabetic group.

Conclusions: : Cilostazol reduces inflammatory reactions and oxidative stress in the development of DR. The anti-inflammatory effects of cilostazol is supposed to be mediated by the inhibition of NF-ΚB activity, and the subsequent decrease in inflammatory mediators such as ICAM-1, MCP-1 and FKN expression in the retina. Cilostazol may be clinically applied in the treatment of diabetic patients to avoid visual loss due to DR.

Keywords: diabetic retinopathy • antioxidants • inflammation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×